Perspective Therapeutics, Inc. (CATX) stock
Close on Nov 20, 2026Market cap $86.05MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $86.05M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.27
- Dividend yield
- –
- Free cash flow yield
- -140.84%
Fundamentals
- Net income
- -$116.43M
- EPS, diluted
- -$1.32
- Free cash flow
- -$121.19M
- Book value per share
- $2.68
- Diluted shares
- 121M
Trading
- Next earnings
- Mar 15, 2027 (estimated, after the close)
- Previous close
- $0.78
- Open
- $0.76
- Day's range
- $0.74 – $0.79
- Volume
- 1,396,520
- Average volume (20 days)
- 4,419,320
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.11
- 52-week range
- $0.73 – $6.16
- RSI (14 days)
- 25.4
- Volatility (1 year)
- 112.2%
- Relative volume
- 0.63×
- WACC
- 10.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.
| Period | CATX | S&P 500 | Difference | CATX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -67.2% | -10.3% | −56.9 pts | ||
| 3 months | -76.5% | -9.3% | −67.2 pts | ||
| Year to date | -72.6% | +1.9% | −74.5 pts | ||
| 1 year | -64.4% | +6.9% | −71.3 pts | ||
| 3 years | -69.8% | +57.5% | −127.3 pts | -32.9% | +16.3% |
| 5 years | -84.6% | +57.3% | −141.9 pts | -31.2% | +9.5% |
| 10 years | -86.8% | +269.7% | −356.5 pts | -18.3% | +14.0% |
Fifteen years at a glance
Fiscal years 2010 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Perspective Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- News
About Perspective Therapeutics
Pharmaceutical Preparations
Perspective Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted alpha therapies and alpha-particle therapeutic drug candidates to treat serious diseases. Its pipeline of investigational drug product candidates includes PSV359, VMT-α-NET, and VMT01, which are undergoing research and clinical evaluation. The company conducts research, clinical development, and finishing operations for its therapeutic assets, supported by subsidiaries including Viewpoint Molecular Targeting, Inc. and Isoray Medical, Inc. Its intended end users and customers encompass patients participating in clinical trials, physicians, healthcare payors, and major treatment centers.
Company profile, executives and historyPerspective Therapeutics stock: common questions
What is Perspective Therapeutics's stock price?
CATX closed at $0.75 on Nov 20, 2026, down 3.85% on the day. Over the past 52 weeks it traded between $0.73 and $6.16.
What is Perspective Therapeutics's market cap?
Perspective Therapeutics was worth $86.05M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.
What is CATX's P/E ratio?
Perspective Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.32), so it has no meaningful P/E ratio.
Does Perspective Therapeutics pay a dividend?
No. Perspective Therapeutics has not paid a cash dividend over the last twelve months.
When does Perspective Therapeutics report earnings next?
Perspective Therapeutics is expected to report Q4 FY2026 results on Mar 15, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has CATX stock performed over the past year?
Including dividends, CATX returned -64.4% over the past year, against +6.9% for the S&P 500.
How many CATX shares are sold short?
9M shares were sold short at the latest FINRA report, 8.58% of the float, or 2.5 days of average trading volume.
Who are Perspective Therapeutics's competitors?
Companies most similar to Perspective Therapeutics by business, industry and size include CLRB, COGT, NBP, APVO, PHIO.
See a number that looks wrong?